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Abstract The WNT signalling pathway is involved in
many physiological and pathophysiological activities. WNT
ligands bind to Frizzled receptors and co-receptors (LDL
receptor-related protein 5/6), triggering a cascade of
signalling events. The major effector of the canonical
WNT signalling pathway is the bipartite transcription factor
β-catenin/T cell transcription factor (β-cat/TCF), formed by
free β-cat and one of the four TCFs. The WNT pathway is
involved in lipid metabolism and glucose homeostasis, and
mutations in LRP5 may lead to the development of diabetes
and obesity. β-Cat/TCF is also involved in the production
of the incretin hormone glucagon-like peptide-1 in the
intestinal endocrine L cells. More recently, genome-wide
association studies have identified TCF7L2 as a diabetes
susceptibility gene, and individuals carrying certain TCF7L2
single nucleotide polymorphisms could be more susceptible
to the development of type 2 diabetes. Furthermore, β-cat is
able to interact with forkhead box transcription factor sub-
group O (FOXO) proteins. Since FOXO and TCF proteins
compete for a limited pool of β-cat, enhanced FOXO
activity during ageing and oxidative stress may attenuate
WNT-mediated activities. These observations shed new light
on the pathogenesis of type 2 diabetes as an age-dependent
disease.






FOXO forkhead box transcription factor subgroup O
GLP-1 glucagon-like peptide-1
GSK-3 glycogen synthase kinase-3
GWA genome-wide association
LEF-1 lymphoid enhancer-binding factor 1
LRP LDL receptor-related protein
LUC luciferase
Pdx-1 pancreas/duodenum homeobox protein 1
PI3K phosphatidylinositol 3-kinase
PKB protein kinase B
ROS reactive oxygen species
SNP single nucleotide polymorphism
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Introduction to the WNT signalling pathway
The WNT signalling pathway (referred to as the WNT
pathway hereafter) was initially recognised in colon cancer
research and in embryonic development studies of the fruit
fly (Drosophila melanogaster), frog (Xenopus laevis) and
other organisms [1, 2]. Aberrant activation of the WNT
pathway may lead to the development of colorectal and other
types of tumours [3]. The major effector of the canonical
WNT pathway is the bipartite transcription factor β-catenin/
T cell factor (β-cat/TCF). This is formed by the heterodimer-
isation of free β-cat with one of the four members of the TCF
family (TCF7 [also known as TCF-1], lymphoid enhancer-
binding factor 1 [LEF-1], TCF7L1 [also known as TCF-3]
and TCF7L2 [also known as TCF-4]), TCF7L2 being the
major partner of β-cat in the intestinal epithelia [3, 4]. As
shown in Fig. 1a, in the absence of WNT, the cellular con-
centration of free β-cat is tightly controlled by a ‘destructive
complex’, consisting of the tumour suppressor adenomatous
polyposis coli (APC), axin, the serine threonine kinase glyco-
gen synthase kinase-3 (GSK-3), casein kinase-1α (CK-1α) and
phosphorylated ERK (pERK) [5, 6]. This complex interacts
with β-cat and phosphorylates it. The phosphorylated β-cat is
then destroyed via the proteasome-mediated degradation
process. The WNT ligands exert their effect via the Frizzled
receptors and the LDL receptor-related protein 5/6 (LRP5/6)
co-receptors (Fig. 1b). Following receptor binding, WNT sig-
nals are transmitted by the association of WNT receptors with
Dishevelled protein (Dvl). This event triggers the disruption of
the destructive complex, preventing the phosphorylation-
dependent degradation of β-cat [4], which then enters the
nucleus and interacts with a member of the TCF family to
form a complex that stimulates the β-cat/TCF (or WNT)
downstream target genes (Fig. 1b).
Many in vitro and in vivo examinations have shown that
several components of the WNT pathway are involved in
pancreatic beta cell proliferation [7–9], normal cholesterol
metabolism and glucose-induced insulin secretion [10] and
the production of the incretin hormone glucagon-like
peptide-1 (GLP-1) [4, 11–13]. More recently, extensive
genome-wide association (GWA) studies have identified
TCF7L2 as a type 2 diabetes susceptibility gene. Of all the
polymorphisms studied to date, TCF7L2 polymorphisms
have been demonstrated to have by far the biggest effect on
the risk of developing type 2 diabetes [14–20]. In addition,
the human LRP5 gene was mapped to within the IDDM4
region, which is linked to type 1 diabetes on chromosome
11q13 [21–23]. Polymorphisms in LRP5 have been shown to
be associated with obesity phenotypes, andmissense mutations
in LRP6 have been shown to be associated with the risk of
bone loss, early coronary disease and the metabolic syndrome
[24, 25]. Moreover, polymorphisms in Wnt5B have been
shown to be associated with the risk of type 2 diabetes [26].
The WNT pathway co-receptors (LRP5/6), a WNT 
ligand (WNT5B), and the major component of the WNT 
pathway  effector  (TCF7L2), are evidently  involved  in 
preventing the development of type 2 diabetes and other 
metabolic diseases
Glossary 
•    -cat/TCF This bipartite transcription factor functions
as the major effect of the canonical WNT signalling 
pathway. It is formed by free β-catenin (β-cat) and a T
cell factor (TCF)
• FOXO Forkhead box transcription factors subgroup O
are mediators of stress. FOXO proteins compete with 
TCF proteins for the limited pool of free β-cat
• Frizzled Frizzled proteins (11 different kinds in
mammals) receptors with seven transmembrane domains. 
WNTs can bind the cysteine-rich domain of Frizzled, an
extracellular part of the receptor
• LRP5/6 Low-density lipoprotein receptor-related
proteins. They are co-receptors of the WNT ligands
• S33Y   -cat A constitutive active mutant of β-cat that
is resistant to proteasome-mediated degradation
• TCF There are four T cell factors (TCFs) in mammals,
namely, TCF7 (also known as TCF-1), LEF-1, TCF7L1
(also known as TCF-3) and TCF7L2 (also known as
TCF-4). In the absence of β-cat, a TCF protein binds to
the consensus sequence (CTTTG[A/T][A/T]) in the WNT
target gene promoters and represses their expression.
β-Cat is able to convert a TCF protein into a transcript- 
ional activator
• TCF7L2 Also known as TCF-4. Recent genome-wide
association studies revealed that polymorphisms in 
TCF7L2 have by far the biggest effect on the risk of type
2 diabetes
• WNT  WNT glycoproteins (encoded by 19 different
genes in mammals) function as ligands for the WNT 
signalling pathway. Although certain WNT ligands can
stimulate c-Jun NH2-terminal kinase (JNK), calcium and
protein kinase C signalling pathways, this review only
discusses the role of the canonical WNT pathway, which
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In this review, I will first discuss the laboratory experimen-
tal studies on the role of theWNT pathway in the development/
genesis of mouse pancreatic islets, pancreatic beta cell growth
and the production of the incretin hormone glucagon-like
peptide-1 (GLP-1). This will be followed by a brief summary
of GWA studies of TCF7L2 and the risk of type 2 diabetes.
Finally, I will discuss recent findings indicating that forkhead
box transcription factor subgroupO (FOXO) and TCF proteins
are able to compete for the limited pool of β-cat, and ageing
will lead to increased FOXO-mediated gene transcription and
reduced TCF-mediated gene transcription. These findings give
us new insights into type 2 diabetes as an age-dependent disease.
WNT signalling is involved in the genesis of pancreatic
islets and the proliferation of pancreatic beta cells
Investigations into how β-cat, the major effector of WNT
signalling, influences pancreatic islet development using
transgenic and knockout mice has produced inconsistent
results. Although several WNT ligands and the Frizzled
receptors were shown to be produced in the embryonic and
postnatal pancreas [27–29], an early study showed that the
loss of β-cat did not significantly perturb pancreatic islet
endocrine cell mass or function, although β-cat is essential
for pancreatic exocrine acinar cell development [30].
Utilising the pancreatic and duodenal homeobox protein 1
(Pdx1)–Cre system to specifically delete the gene encoding
β-cat (Ctnnb1) in the epithelium of the pancreas and
duodenum revealed that Ctnnb1-deleted cells had a com-
petitive disadvantage during pancreas development [31].
Although there was a reduction in endocrine islet numbers
during early embryonic development and the mice devel-
oped pancreatitis perinatally because of the disruption of
acinar epithelial structure, the mice later recovered from the
pancreatitis and regenerated normal pancreas and duodenal
villi from the wild-type cells that escaped the Ctnnb1
deletion [31]. However, a more recent study found that
inducing the production of a stabilised form ofβ-cat (a mutant
one that is more resistant to the proteasome-mediated
degradation process) at different stages of development has
different effects. During the early stage of organogenesis,
robust production of stabilised β-cat drives changes in
Hedgehog and fibroblast growth factor signalling and blocks
the expression of the gene encoding Pdx-1, an important
homeodomain protein transcription factor involved in the
genesis of pancreatic beta cells. Induction of the stabilised
form of β-cat at a later time point in pancreas development
enhances proliferation and increases the size of this organ [32].
Seemingly contradictory results can be resolved if we
assume that β-cat and β-cat/TCF exert different functions
in a very precise dose-dependent manner at different
developmental stages. It appears that mouse embryo is
able to overcome a substantial reduction in β-cat via
complicated compensatory mechanisms, which allow the
generation of a normal pancreas
A WNT target gene A WNT target gene
TCF/LEF TCF/LEF
β -cat





















Fig. 1 Summary of the canonical WNT pathway. a In the absence of
WNT stimulation, β-cat is located within the ‘destructive complex’,
phosphorylated by GSK-3, CK-1α and pERK, and subsequently
destroyed by proteasome-mediated protein degradation. b Following
WNT stimulation, the phosphorylation/destructive complex disassem-
bles. This results in an accumulation of free β-cat, which enters the
nucleus and forms the bipartite transcription factor β-cat/TCF, leading
to enhanced expression of the WNT target genes. APC, adenomatous
polyposis coli; pERK, phosphorylated ERK
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Rulifson et al. recently examined the effect of WNT sig-
nalling in regulating beta cell genesis and proliferation using
both in vitro and in vivo approaches [7]. Purified WNT3a
(which is known to activate the canonical WNT pathway)
stimulated proliferation of both themouse beta cell lineMIN6
and primary mouse pancreatic beta cells, possibly through
the cell cycle regulators cyclin D1, cyclin D2 and cyclin-
dependent kinase 4, as well as the homeodomain tran-
scription factor Pitx2. Immunohistological examinations of
3-month-old bi-transgenic rat insulin I promoter (RIP)-Cre
and β-catactive mice revealed a threefold increase in the
production of Ki67 by pancreatic beta cells, which occurred
in parallel with a 2.5-fold increase in beta cell mass [7].
Furthermore, axin production led to impaired Pitx2 gene ex-
pression, along with impaired beta cell expansion [7]. Taken
together, these observations suggest that WNT signalling is
necessary and sufficient for pancreatic beta cell proliferation.
The incretin hormone GLP-1 has been shown to
stimulate WNT activity in adult mouse pancreatic islets,
and both TCF7L2 and β-cat are required for GLP-1-
stimulated proliferation of the rat pancreatic beta cell line
INS-1 [9]. Furthermore, adipocyte-derived WNT molecules
have been reported to induce beta cell proliferation and
insulin secretion in vitro [33].
In vivo mouse and in vitro cell line studies have revealed
the essential function of WNT signalling in pancreatic
beta cells during embryonic developmental stages and in 
adulthood
The WNT co-receptor LRP5 is essential for normal lipid
metabolism and glucose-induced insulin secretion
Besides the effectors of WNT signalling, the co-receptors of
the WNT ligands, LRP-5/6 [34, 35], are also important for
normal lipid and glucose metabolism. An early study
demonstrated that loss of function mutations of LRP5 were
associated with the development of the autosomal recessive
disorder osteoporosis-pseudoglioma syndrome [36]. The
co-receptor was shown to be important in transducing WNT
signalling and to play critical roles in modulating bone
accrual and eye development [37]. The human LRP5 gene
maps within the IDDM4 region on chromosome 11q13,
which is linked to type 1 diabetes [21–23]. A recent GWA
study has also shown that polymorphisms in LRP5 are
associated with obesity phenotypes [38]. Pancreatic pro-
duction of LRP5 has been reported [39, 40].
It has been demonstrated that LRP5 can interact with
axin, one of the inhibitors of the WNT pathway (Fig. 1).
When Lrp5 was expressed in fibroblast cells, the LRP5
protein alone exerted no effect on the WNT pathway, but
acted synergistically with the WNT ligands [41]. Further-
more, LRP5 molecules without the extracellular domain
were constitutively active. They induced TCF/LEF-mediat-
ed transcription and stabilised β-cat [41]. The addition of
WNT ligands to the medium triggered the translocation of
axin to the cell membrane and enhanced the interaction
between axin and LRP5. Finally, the LRP5 domain
involved in the interaction with axin is also required for
TCF/LEF-mediated transcriptional activation. These obser-
vations collectively suggest that binding of axin by LRP5
and its translocation to the cell membrane is an important
part of WNT signal activation [41] (Fig. 1b).
After being fed a high-fat diet, Lrp5−/− mice showed
increased plasma cholesterol levels and after being fed a
normal diet they showed markedly impaired glucose
tolerance [10]. Furthermore, in response to the administra-
tion of high concentrations of glucose, the mice showed
significant reductions in intracellular ATP and calcium
levels and decreased glucose-induced insulin secretion [10].
The WNT ligands WNT3a and WNT5a stimulated insulin
secretion in the wild-type mice but not in the LRP5−/− mice
[10], suggesting that WNT ligands require a functional
LRP5 to regulate insulin secretion.
In mice, functional LRP5 is important for normal lipid
and glucose metabolism. In humans, mutations in LRP5
may result in obesity, type 1 diabetes and other
metabolic diseases
Both WNT and insulin pathways are involved
in the production of the incretin hormone GLP-1
GLP-1 is an important incretin hormone that is encoded by
the Gcg gene, which is expressed in the intestinal endocrine
L cells [42–44]. In these cells, expression of Gcg mRNA and
production of GLP-1 can be activated by lithium, which
mimics the function of the WNT ligands [45], or the
overproduction of the constitutively active S33Y β-cat
mutant [12], indicating that Gcg is a downstream target of
the WNT signalling pathway. Activation was subsequently
attributed to a TCF binding site within the G2 enhancer
element of the Gcg promoter and the production of TCF7L2
in the intestinal endocrine L cells [4]. It is well known that
Gcg expression and GLP-1 production can be activated by
elevations in cAMP levels [46–52]. Since the G2 enhancer
element has been shown to mediate the stimulatory effect of
both cAMP and calcium on Gcg promoter activity [53], it is
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possible that cAMP pathway cross-talks with the WNT
pathway to regulate Gcg expression [12].
Insulin inhibits Gcg expression in pancreatic alpha cells
[54, 55]. This inhibition is physiologically important because
Gcg mRNA expression in pancreatic islets leads to the
production of glucagon, the primary counter-regulatory
hormone of insulin [54, 55]. A recent study showed a
significant stimulatory effect of insulin on Gcg mRNA
expression and GLP-1 production in intestinal L cells.
Interestingly, insulin activated a Gcg–luciferase (LUC)
reporter gene construct containing the wild-type TCF binding
site within the G2 enhancer element of the Gcg promoter, but
not the one carrying a mutation at this site. Either ‘knocking-
down’ β-cat production or the function of TCF7L2 com-
pletely blocked insulin-stimulated intestinal Gcg expression.
Thus, insulin, at least partially uses effectors of the WNT
pathway to exert this stimulatory effect [13]. Interestingly, the
stimulatory effect of insulin on Gcg promoter activity was
blocked by phosphatidylinositol 3-kinase (PI3K) inhibition,
but not by protein kinase B (PKB) inhibition [13]. This, along
with the observations of the existence of PKB-independent
PI3K activity in other cell lineages [56–58], suggest that an
unknown signalling component mediates PI3K-mediated
cross-talk between insulin and WNT signalling pathways
[13]. In hyperinsulinaemic and insulin-resistant MKR mice
[59, 60], Gcg mRNA expression and GLP-1 production in
the distal ileum were significantly higher than in sex- and
age-matched controls [13], indicating that hyperinsulinaemia
and/or insulin resistance may affect the homeostasis of GLP-1
production. Figure 2 shows that both WNT and cross-talk
between insulin and WNT are involved in GLP-1 production,
although detailed mechanisms and the pathophysiological
significance of the cross-talk need to be further explored.
Figure 2 also shows that lithium and cAMP may stimulate
Gcg expression by affecting the production of free β-cat.
It appears that β-cat/TCF functions as the effector of other 
signalling pathways to regulate Gcg expression and GLP-1 
production. It is likely that cross-talk between insulin and
WNT pathways is involved in the homeostasis of GLP-1
production
TCF7L2 polymorphisms are associated with the risk
of type 2 diabetes
In 2006, a study reported that inheritance of specific single
nucleotide polymorphisms (SNPs) within the TCF7L2 gene
was related to an increased risk of type 2 diabetes [20]. The
investigators of this study have genotyped 228 microsatellite
markers in Icelandic individuals with type 2 diabetes and
healthy controls across a 10.5 Mb interval on chromosome
10q. A microsatellite, DG10S478, located within the intron 3
region of TCF7L2, was found to be associated with type 2
diabetes [20]. This observation was subsequently replicated in
both a Danish and US cohort [20]. The investigators found
that two of five SNPs investigated within introns 4 and 5 of
TCF7L2, namely rs12255372 and rs7903146, were in strong
linkage disequilibrium with DG10S478 and showed similarly
robust associations with type 2 diabetes [20]. This discovery
has drawn attention globally [15–19, 61–71], and studies in
many other ethnic groups have confirmed that rs12255372
and rs7903146 are the two SNPs most strongly associated
with type 2 diabetes [72, 73], with the SNP rs7903146
reported to have the greatest effect in white individuals [73,
74]. The two SNPs occur at relatively low frequencies in
Asian populations, although an association with type 2
diabetes was identified in two large Japanese cohorts [75,
76]. Recent studies have revealed two novel SNPs associated
with the risk of type 2 diabetes. The SNP rs290487 was
identified in a study of a Han Chinese population in Taiwan
[77], and the SNP rs11196218 was identified in a study of
Hong Kong Chinese individuals [78]. It has been reported
that non-diabetic carriers of the risk-associated TCF7L2 SNPs
do not have defects in GLP-1 secretion [64].
All the SNPs identified to date in TCF7L2 are located
within the intron regions of the gene. How these SNPs 
affect the expression of TCF7L2, and therefore the risk















Fig. 2 Multiple signalling cascades utilise β-cat/TCF as the effector
for the regulation of Gcg expression. Both WNT and LiCl increase
levels of free β-cat through inhibition of GSK-3. Hormone and
neurotransmitters (H/NT) may enhance β-cat/TCF activity by inter-
acting with their G-protein-coupled receptors (GPCRs). Insulin may
enhance the translocation of β-cat into the nucleus. The question
marks indicate that detailed mechanisms for these events are still
under investigation. IR, insulin receptor
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Since TCF7L2 is known as an intestinal cell specific
transcription factor [79] and is an important regulator of
intestinal Gcg expression and GLP-1 production [11], it
was suggested that the TCF7L2 SNPs may modify disease
susceptibility by affecting intestinal Gcg expression and
plasma levels of GLP-1 [20]. More recently, genotyping
1,100 non-diabetic German individuals for the five known
TCF7L2 SNPs indicated that TCF7L2 variants are as-
sociated with reduced insulin secretion [64]. In contrast,
plasma GLP-1 levels during an OGTT were not signifi-
cantly influenced by the TCF7L2 variants [64]. The CT/TT
genotypes of the SNP rs7903146 were shown to strongly
predict future type 2 diabetes in two independent Scan-
dinavian cohorts [63]. The risk T allele was associated
with impaired insulin secretion, incretin effects, and an
enhanced rate of hepatic glucose production [63]. Further-
more, investigators found that islet TCF7L2 expression was
increased fivefold in individuals with the TT genotype.
Although TCF7L2 expression was positively correlated
with the expression of INS, which encodes insulin, it was
inversely correlated with glucose-stimulated insulin release
[63]. Furthermore, an ex vivo examination demonstrated that
TCF7L2 knockdown (with small interfering RNA) increased
human pancreatic beta cell apoptosis and reduced beta cell
proliferation and glucose-stimulated insulin secretion [8].
Overexpression of TCF7L2, on the other hand, protected
islets from glucose- and cytokine-induced apoptosis and from
impaired functions [8]. As discussed above, both TCF7L2
and β-cat are required as effectors for GLP-1-stimulated beta
cell proliferation [9].
Although these recent studies indicate that TCF7L2
SNPs may directly affect INS expression and/or insulin
secretion, we still do not have a clear picture of how these
SNPs affect the function of pancreatic beta cells. As
discussed by Schafer and colleagues, the involvement of
changes in GLP-1 production and secretion influenced by
TCF7L2 variants in the increased risk of type 2 diabetes
cannot be eliminated [64]. It should also be pointed out that
the participants in their study were non-diabetic individuals.
It is possible that a certain compensatory response(s)
attenuated the defect in GLP-1 secretion in these TCF7L2
SNP carriers in the pre-diabetic stages.
FOXOs compete with TCFs for the limited pool of β-cat
Over the last few years, investigations have led to the
discovery of the insulin–FOXO protein signalling cascade
[80–83]. This regulatory system controls metabolic homeo-
stasis and other important physiological and pathophysio-
logical events. In the absence of insulin or growth factors,
FOXOs are mainly located within the nuclei and upregulate
the expression of a set of target genes, thereby promoting
cell cycle arrest, stress resistance and apoptosis (Fig. 3a). In
the presence of insulin or growth factors, FOXOs are
phosphorylated by PKB and serum- and glucocorticoid-
regulated protein kinase and stay in the cell cytosol
(Fig. 3b) [81]. In this way, FOXOs function to control the
growth, development, metabolism, and possibly, longevity
of the cell and the organism in response to insulin, insulin-
like growth factor-1 and many other growth factors [81]. In
contrast to the effect on insulin signalling, oxidative stress
induces the activation of FOXO signalling [84]. It appears
that this is due to the activation of the small GTPase Ral,
which leads to the c-Jun NH2-terminal kinase (JNK)-
dependent phosphorylation of FOXOs, followed by their
translocation to the nucleus and increased FOXO-mediated
transcriptional activities [84].
An evolutionarily conserved interaction between the
WNT pathway effector β-cat and FOXOs was discovered
in 2005 [85]. In mammalian cells, a yeast two-hybrid screen
detected an interaction between β-cat and FOXO1 and
FOXO3. The gene bar-1 (also known as C54D1.6) encodes
the Caenorhabditis elegans (nematode worm) homologue
of β-cat [86], while the FOXO gene homologue in this
organism is daf16 [87]. An interaction between BAR-1
and DAF16 was also detected [85]. In mammalian cells,
binding of β-cat to FOXO enhanced the transcriptional
activity of FOXO. In C. elegans, the loss of BAR-1 reduced
the activity of DAF16 in dauer formation and life span [85].
More importantly, the association between β-cat and FOXO
was shown to be enhanced in cells exposed to oxidative
stress [85].
The interaction between FOXO and β-cat prompted
scientists to explore the pathophysiological role of this
interaction in age-dependent diseases, including osteoporo-
sis. It was reported that male and female mice with sufficient
sex hormones could still lose bone mass and strength
progressively during the ages of 4–31 months, and that this
was associated with enhanced osteoblast and osteocyte
apoptosis, reduced osteoblast number and bone formation
rate, and elevated levels of reactive oxygen species (ROS)
[88]. Furthermore, in the C57BL/6 mice, ageing was shown
to be associated with the reduced expression of several
WNT target gene mRNAs, including Axin2 and Opg (also
known as Tnfrsf11b); and increased expression of the
FOXO target genes, such as Gadd45 (also known as
Gadd45a) [89]. However, hydrogen peroxide treatment in
an uncommitted mesenchymal cell line, C2C12, increased
FOXO-mediated transcription and attenuated both basal
and WNT3A-stimulated levels of Axin2 and other WNT
target genes. Opposite effects of hydrogen peroxide on
FOXO- and TCF-mediated transcription were confirmed by
measuring the reporter gene activity of FOXO-LUC and
TCF-LUC in response to different dosages of hydrogen
peroxide. More recently, the concept of that the interaction
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of FOXO with β-cat inhibits β-cat/TCF activity was further
confirmed [90]. It has been demonstrated that small
interfering RNA (siRNA)-mediated knockdown of FOXO
reverted the loss of β-cat binding to TCF after cellular
oxidative stress [90]. The production and function of
FOXO proteins in the pancreatic beta cells have been
extensively investigated during the past few years [91]. It
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Fig. 3 Schematic representation of FOXO signalling. a Without
insulin or a growth factor, FOXO enters the nucleus, binds to the
forkhead response element (FHRE) of its downstream target genes.
The activation of these genes (such as p27 [also known as Cdkn1b],
Bim [also known as Bcl2l11], Gadd45 and Fasl) will lead to cell cycle
arrest, stress resistance and cell apoptosis. b Insulin (Ins), insulin-like
growth factor-1 (IGF-1) and other growth factors (GFs) are able to
activate the PI3K–PDK-1–PKB signalling pathway. Both PKB and
serum- and glucocorticoid-inducible kinase (SGK) phosphorylate


















Fig. 4 Insulin/growth factors control the balance between FOXO- and
TCF-mediated gene expression. FOXOs and TCFs compete for the
limited pool of β-cat. During ageing and oxidative stress, the
production of ROS leads to increased FOXO-mediated gene tran-
scription and reduced TCF-mediated gene transcription. This will lead
to reduced WNT activity, which is important for lipid and glucose
metabolism, pancreatic beta cell proliferation and function and the
production of the incretin hormone GLP-1. Insulin/growth factors
(GFs) help to restore the balance by two means. First, they stimulate
the nuclear exclusion of FOXOs via phosphorylation mediated by
PKB/serum- and glucocorticoid-inducible kinase (SGK) [81, 82, 91].
Second, they enhance the nuclear content of β-cat and the binding of
β-cat/TCF to the WNT target gene promoters via a yet to be identified
PKB-independent mechanism [13]
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factors control the balance between FOXO-mediated and
WNT-mediated gene transcription (see below).
FOXOs and TCF proteins compete for the common co- 
factor β-cat, while insulin/growth factors inhibit FOXO- 
mediated gene expression by trapping FOXOs in the cell
cytosol
Summary and perspective
Comprehensive in vitro and in vivo studies by multiple
laboratories have shown that WNT signalling is important
in normal pancreatic islet development, as well as in
pancreatic beta cell function and genesis. It appears that
the WNT/β-cat pathway plays direct, precise, and even
opposing roles during different stages of pancreatic islet
development [32]. Obviously, to exert such precise and
opposing effects, WNT/β-cat signalling needs to interact
with other signalling pathways and regulate the down-
stream gene expression profiles, both temporally and
spatially.
WNT signalling is also important in activating intestinal
Gcg transcription and, therefore, the production of the
incretin hormone GLP-1 [11–13], which has been shown to
utilise WNT signalling effectors, i.e. β-cat/TCF7L2, to exert
its effect on beta cell proliferation [9]. Further examinations
are required to verify whether TCF7L2, certainWNT ligands
and Frizzled receptors are also involved in the genesis of
pancreatic islets and intestinal endocrine L cells.
GWA have revealed relationships between SNPs in
LRP5, which encodes a co-receptor of the WNT ligands,
and the risk of type 1 diabetes [22, 23], as well as obesity
[29]. LRP6 mutations are possibly related to the develop-
ment of bone loss, coronary disease and the metabolic
syndrome [24, 25]. More importantly, extensive recent
studies have identified associations between SNPs in
TCF7L2 and the risk of type 2 diabetes. These observations
suggest that WNT signalling is not only involved in
pancreatic islet development during embryogenesis, but
also in the function of pancreatic and intestinal endocrine
cells during adulthood. Since all the known risk-associated
SNPs of TCF7L2 are located within the intronic regions,
the effect of these SNPs on TCF7L2 expression should be
examined. To ultimately understand why these SNPs affect
the risk of type 2 diabetes, we need to explore mechanisms
underlying TCF7L2 production in pancreatic and intestinal
endocrine cells under both physiological and pathological
conditions.
Type 2 diabetes is a chronic and age-dependent disease.
As shown in Fig. 4, nuclear FOXOs increase during ageing
because of the accumulation of ROS and JNK signalling
pathway activation [92]. FOXOs compete with TCF
proteins, including TCF7L2, for the limited pool of β-cat.
This leads to reduced WNT activity, which is important for
lipid and glucose metabolism, pancreatic beta cell prolifer-
ation and function, and the production of the incretin
hormone GLP-1. Insulin and growth factors, on the other
hand, may restore the balance between FOXO- and TCF-
mediated gene transcription by trapping FOXOs within the
cell cytosol. The establishment of this concept offers a new
perspective on the pathogenesis of type 2 diabetes and other
age-dependent diseases. Further examination of the cross-
talk between insulin/growth factors and WNT signalling
pathways may lead to the development of novel therapeutic
approaches for the treatment of type 2 diabetes and other
age-dependent diseases.
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